Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (126)	9/1/2000 8:16:26 AM
From: blue_chip	Respond to of 164

News Release Oncolytics Biotech Inc. Receives U.S. Patent Approval Oncolytics Biotech Inc ONC Shares issued 16,919,080 Aug 31 close $12.40 Fri 1 Sept 2000 News Release Mr. Matt Coffey reports The U.S. Patent and Trademark Office has issued patent 6,110,461 to Oncolytics effective Aug. 29, 2000. The patent covers the pharmaceutical use of the reovirus in the treatment of Ras-mediated cancers in mammals. "The issuance of this patent provides us with our initial proprietary position with respect to the development of reovirus as a therapeutic for the treatment of cancer," said Dr. Matt Coffey, vice-president, product development. "It is exciting and gratifying to receive approval for these broad-based claims. It solidifies our platform by providing intellectual property protection and removes an important element of risk in the development and commercialization process." WARNING: The company relies on litigation protection for "forward-looking" statements. *Onc is 35% owned by Syb More info at thenextwave.emerchantpro.com regards chip

To: Jim Oravetz who wrote (126)	9/6/2000 10:14:37 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 164

It is estimated that 3.5 million people suffer C. difficile infections annually in North America and in 20% of these infections (700,000 cases) the condition can progress to severely recurrent CDAD. This condition is thought to affect approximately 1.65 million people a year in North America, Japan and Europe. Most of these cases occur in hospitals, causing extended patient stays and greater health care costs. There is presently no suitable treatment for the recurrent form as the bacterium forms robust spores that are resistant to conventional antibiotics. There is therefore intense interest among clinicians and patients in novel, effective, and safe treatments to help with C. difficile disease control. smallcapsonline.com From WORD document under SYBBF. Jim